Pro-phagocytic Effects of Thymoquinone on Cigarette Smoke-exposed Macrophages Occur by Modulation of the Sphingosine-1-phosphate Signalling System

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 13, Issue 5, 2016, Pages 653-661

  Barnawi, Jameel ^a,b,c   Tran, Hai B ^a   Roscioli, Eugene ^a   Hodge, Greg ^a,b   Jersmann, Hubertus ^a,b   Haberberger, Rainer ^d   Hodge, Sandra ^a,b  

^a HANSON INSTITUTE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF TABUK   (Saudi Arabia)

^d FLINDERS UNIVERSITY   (Australia)

Author keywords

Chronic obstructive pulmonary disease; cigarette smoke; macrophage; sphingosine 1 phosphate; thymoquinone

Indexed keywords

CIGARETTE SMOKE; LIPOPOLYSACCHARIDE; MESSENGER RNA; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 1; SPHINGOSINE 1 PHOSPHATE RECEPTOR 2; SPHINGOSINE 1 PHOSPHATE RECEPTOR 3; SPHINGOSINE 1 PHOSPHATE RECEPTOR 4; SPHINGOSINE 1 PHOSPHATE RECEPTOR 5; THYMOQUINONE; UNCLASSIFIED DRUG; ANTIOXIDANT; BENZOQUINONE DERIVATIVE; LYSOPHOSPHOLIPID; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE;

ARTICLE; BRONCHUS MUCOSA; CELL PROTECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG ANTAGONISM; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LOW DRUG DOSE; MACROPHAGE; MODULATION; PHAGOCYTOSIS; PRIORITY JOURNAL; SMOKING; ANALOGS AND DERIVATIVES; APOPTOSIS; BRONCHUS; CELL LINE; CYTOLOGY; DRUG EFFECTS; DRUG MIXTURE; EPITHELIUM CELL; GENETICS; METABOLISM; PHARMACOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; SMOKE; TOBACCO;

ANTIOXIDANTS; APOPTOSIS; BENZOQUINONES; BRONCHI; CELL LINE; COMPLEX MIXTURES; EPITHELIAL CELLS; HUMANS; LIPOPOLYSACCHARIDES; LYSOPHOSPHOLIPIDS; MACROPHAGES; PHAGOCYTOSIS; RECEPTORS, LYSOSPHINGOLIPID; RNA, MESSENGER; SIGNAL TRANSDUCTION; SMOKE; SPHINGOSINE; TOBACCO PRODUCTS;

EID: 84965060730     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2016.1153614     Document Type: Article

References (81)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2010. Available from:http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html (accessed December2011).
2. R.A.Pauwels, C.G.Lofdahl, L.A.Laitinen, J.P.Schouten, D.S.Postma, N.B.Pride, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European respiratory society study on chronic obstructive pulmonary disease. N Engl J Med 1999; 340:1948–1953.
3. S.Hodge, G.Hodge, R.Scicchitano, P.N.Reynolds, M.Holmes. Alveolar macrophages from subjects with chronic obstructive pulmonary disease are deficient in their ability to phagocytose apoptotic airway epithelial cells. Immunol Cell Biol 2003; 81:289–296.
4. S.Hodge, G.Hodge, J.Ahern, H.Jersmann, M.Holmes, P.N.Reynolds. Smoking alters alveolar macrophage recognition and phagocytic ability:Implications in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2007; 37:748–755.
5. S.Hodge, G.Hodge, H.Jersmann, G.Matthews, J.Ahern, M.Holmes, et al. Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 178:139–148.
6. S.Hodge, G.Matthews, M.M.Dean, J.Ahern, M.Djukic, G.Hodge, et al. Therapeutic role for mannose-binding lectin in cigarette smoke-induced lung inflammation? Evidence from a murine model. Am J Respir Cell Mol Biol 2010; 42:235–242.
7. S.Hodge, G.Matthews, V.Mukaro, J.Ahern, A.Shivam, G.Hodge, et al. Cigarette smoke-induced changes to alveolar macrophage phenotype and function are improved by treatment with procysteine. Am J Respir Cell Mol Biol 2011; 44:673–681.
8. P.M.Henson, G.P.Cosgrove, R.W.Vandivier. State of the art. Apoptosis and cell homeostasis in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3:512–516.
9. K.Morimoto, W.J.Janssen, M.B.Fessler, K.A.McPhillips, V.M.Borges, R.P.Bowler, et al. Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease. J Immunol 2006; 176:7657–7665.
10. K.Morimoto, W.J.Janssen, M.B.Fessler, Y.Q.Xiao, K.A.McPhillips, V.M.Borges, et al. Statins enhance clearance of apoptotic cells through modulation of Rho-GTPases. Proc Am Thorac Soc 2006; 3:516–517.
11. R.W.Vandivier, P.M.Henson, I.S.Douglas. Burying the dead:the impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease. Chest 2006; 129:1673–1682.
12. S.P.Hart, C.Haslett, I.Dransfield. Recognition of apoptotic cells by phagocytes. Experientia 1996; 52:950–956.
13. S.Knapp, J.C.Leemans, S.Florquin, J.Branger, N.A.Maris, J.Pater, et al. Alveolar macrophages have a protective antiinflammatory role during murine pneumococcal pneumonia. Am J Respir Crit Care Med 2003; 167:171–179.
14. S.Hodge, G.Hodge, M.Holmes, P.N.Reynolds. Increased airway epithelial and T-cell apoptosis in COPD remains despite smoking cessation. Eur Respir J 2005; 25:447–454.
15. K.Imai, B.A.Mercer, L.L.Schulman, J.R.Sonett, J.M.D'Armiento. Correlation of lung surface area to apoptosis and proliferation in human emphysema. Eur Respir J 2005; 25:250–258.
16. L.Segura-Valdez, A.Pardo, M.Gaxiola, B.D.Uhal, C.Becerril, M.Selman. Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest 2000; 117:684–694.
17. N.Yokohori, K.Aoshiba, A.Nagai, R.F.R.GroupRespiratory Failure Research. Increased levels of cell death and proliferation in alveolar wall cells in patients with pulmonary emphysema. Chest 2004; 125:626–632.
18. A.E.Taylor, T.K.Finney-Hayward, J.K.Quint, C.M.Thomas, S.J.Tudhope, J.A.Wedzicha, et al. Defective macrophage phagocytosis of bacteria in COPD. Eur Respir J 2010; 35:1039–1047.
19. A.H.Futerman, Y.A.Hannun. The complex life of simple sphingolipids. EMBO Rep 2004; 5:777–782.
20. Y.A.Hannun, L.M.Obeid. Principles of bioactive lipid signalling:lessons from sphingolipids. Nat Rev Mol Cell Biol 2008; 9:139–150.
21. T.A.Taha, K.M.Argraves, L.M.Obeid. Sphingosine-1-phosphate receptors:receptor specificity versus functional redundancy. Biochim Biophys Acta 2004; 1682:48–55.
22. S.Uhlig, E.Gulbins. Sphingolipids in the lungs. Am J Respir Crit Care Med 2008; 178:1100–1114.
23. Y.Yang, S.Uhlig. The role of sphingolipids in respiratory disease. Ther Adv Respir Dis. 2011; 5:325–344.
24. J.Barnawi, H.Tran, J.Jersmann, S.Pitson, G.Hodge, R.Meech, et al. Potential link between the sphingosine-1-phosphate [S1P] system and defective alveolar macrophage phagocytic function in chronic obstructive pulmonary disease/emphysema [COPD]. plos ONE, in press, 2015.
25. D.N.Petrusca, Y.Gu, J.J.Adamowicz, N.I.Rush, W.C.Hubbard, P.A.Smith, et al. Sphingolipid-mediated inhibition of apoptotic cell clearance by alveolar macrophages. J Biol Chem 2010; 285:40322–40332.
26. I.Petrache, D.N.Petrusca. The involvement of sphingolipids in chronic obstructive pulmonary diseases. Handb Exp Pharmacol 2013:247–264.
27. M.N.Nagi, K.Alam, O.A.Badary, O.A.al-Shabanah, H.A.al-Sawaf, A.M.al-Bekairi. Thymoquinone protects against carbon tetrachloride hepatotoxicity in mice via an antioxidant mechanism. Biochem Mol Biol Int. 1999; 47:153–159.
28. M.M.Sayed-Ahmed, A.M.Aleisa, S.S.Al-Rejaie, A.A.Al-Yahya, O.A.Al-Shabanah, M.M.Hafez, et al. Thymoquinone attenuates diethylnitrosamine induction of hepatic carcinogenesis through antioxidant signaling. Oxid Med Cell Longev 2010;3:254–261.
29. V.Hajhashemi, A.Ghannadi, H.Jafarabadi. Black cumin seed essential oil, as a potent analgesic and antiinflammatory drug. Phytother Res 2004; 18:195–199.
30. C.C.Woo, A.P.Kumar, G.Sethi, K.H.Tan. Thymoquinone:potential cure for inflammatory disorders and cancer. Biochem Pharmacol 2012; 83:443–451.
31. R.Keyhanmanesh, L.Pejman, H.Omrani, Z.Mirzamohammadi, A.A.Shahbazfar. The effect of single dose of thymoquinone, the main constituents of Nigella sativa, in guinea pig model of asthma. Bioimpacts 2014; 4:75–81.
32. S.Kalemci, S.Cilaker Micili, T.Acar, T.Senol, N.Dirican, G.Omeroglu, et al. Effectiveness of thymoquinone in the treatment of experimental asthma. Clin Ther 2013; 164:e155–158.
33. M.El Gazzar, R.El Mezayen, J.C.Marecki, M.R.Nicolls, A.Canastar, S.C.Dreskin. Anti-inflammatory effect of thymoquinone in a mouse model of allergic lung inflammation. Int Immunopharmacol 2006; 6:1135–1142.
34. R.El Mezayen, M.El Gazzar, M.R.Nicolls, J.C.Marecki, S.C.Dreskin, H.Nomiyama. Effect of thymoquinone on cyclooxygenase expression and prostaglandin production in a mouse model of allergic airway inflammation. Immunol Lett 2006;106:72–81.
35. M.El Gazzar, R.El Mezayen, M.R.Nicolls, J.C.Marecki, S.C.Dreskin. Downregulation of leukotriene biosynthesis by thymoquinone attenuates airway inflammation in a mouse model of allergic asthma. Biochim Biophys Acta 2006; 1760:1088–1095.
36. D.El-Khouly, W.M.El-Bakly, A.S.Awad, H.O.El-Mesallamy, E.El-Demerdash. Thymoquinone blocks lung injury and fibrosis by attenuating bleomycin-induced oxidative stress and activation of nuclear factor Kappa-B in rats. Toxicology 2012; 302:106–113.
37. M.Kanter Effects of Nigella sativa seed extract on ameliorating lung tissue damage in rats after experimental pulmonary aspirations. Acta Histochem 2009; 111:393–403.
38. M.Kanter Thymoquinone attenuates lung injury induced by chronic toluene exposure in rats. Toxicol Ind Health 2011; 27:387–395.
39. G.M.Suddek, N.A.Ashry, N.M.Gameil. Thymoquinone attenuates cyclophosphamide-induced pulmonary injury in rats. Inflammopharmacology 2013; 21:427–435.
40. A.El-Mahmoudy, Y.Shimizu, T.Shiina, H.Matsuyama, H.Nikami, T.Takewaki. Macrophage-derived cytokine and nitric oxide profiles in type I and type II diabetes mellitus:effect of thymoquinone. Acta Diabetol 2005; 42:23–30.
41. R.Wilkins, M.Tucci, H.Benghuzzi. The effects of egcg and tq on inflammatory mediator production in raw 264.7 cells challenged with LPS - biomed 2010. Biomed Sci Instrum 2010; 46:208–213.
42. R.Wilkins, M.Tucci, H.Benghuzzi. Role of plant-derived antioxidants on NF-kb expression in LPS-stimulated macrophages - biomed 2011. Biomed Sci Instrum 2011; 47:222–227.
43. S.J.Hodge, G.L.Hodge, M.Holmes, P.N.Reynolds. Flow cytometric characterization of cell populations in bronchoalveolar lavage and bronchial brushings from patients with chronic obstructive pulmonary disease. Cytometry B Clin Cytom 2004; 61:27–34.
44. S.Hodge, G.Hodge, S.Brozyna, H.Jersmann, M.Holmes, P.N.Reynolds. Azithromycin increases phagocytosis of apoptotic bronchial epithelial cells by alveolar macrophages. Eur Respir J 2006; 28:486–495.
45. H.B.Tran, M.D.Lewis, L.W.Tan, S.E.Lester, L.M.Baker, J.Ng, et al. Immunolocalization of NLRP3 Inflammasome in Normal Murine Airway Epithelium and Changes following Induction of Ovalbumin-Induced Airway Inflammation. J Allergy (Cairo) 2012; 2012:819176.
46. H.B.Tran, J.Ahern, G.Hodge, P.Holt, M.M.Dean, P.N.Reynolds, et al. Oxidative stress decreases functional airway mannose binding lectin in COPD. PLoS ONE. 2014; 9:e98571.
47. I.Rahman, W.MacNee. Role of transcription factors in inflammatory lung diseases. Thorax 1998; 53:601–612.
48. F.M.Moodie, J.A.Marwick, C.S.Anderson, P.Szulakowski, S.K.Biswas, M.R.Bauter, et al. Oxidative stress and cigarette smoke alter chromatin remodeling but differentially regulate NF-kappaB activation and proinflammatory cytokine release in alveolar epithelial cells. FASEB J 2004; 18:1897–1899.
49. I.Rahman. Antioxidant therapeutic advances in COPD. Ther Adv Respir Dis 2008; 2:351–374.
50. P.J.Barnes. Alveolar macrophages as orchestrators of COPD. COPD 2004; 1:59–70.
51. P.J.Barnes Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 2004; 56:515–548.
52. C.Bazzini, V.Rossetti, D.A.Civello, F.Sassone, V.Vezzoli, L.Persani, et al. Short- and long- term effects of cigarette smoke exposure on glutathione homeostasis in human bronchial epithelial cells. Cell Physiol Biochem 2013; 32:129–145.
53. M.Bondi, M.Ferraro, S.Di Vincenzo, S.Gerbino, G.Cavallaro, G.Giammona, et al. Effects in cigarette smoke stimulated bronchial epithelial cells of a corticosteroid entrapped into nanostructured lipid carriers. J Nanobiotechnology 2014; 12:46.
54. L.Zhang, X.Guo, W.Xie, Y.Li, M.Ma, T.Yuan, et al. Resveratrol exerts an anti-apoptotic effect on human bronchial epithelial cells undergoing cigarette smoke exposure. Mol Med Rep 2015; 11:1752–1758.
55. F.D'Agostini, R.M.Balansky, A.Izzotti, R.A.Lubet, G.J.Kelloff, S.De Flora. Modulation of apoptosis by cigarette smoke and cancer chemopreventive agents in the respiratory tract of rats. Carcinogenesis 2001; 22:375–380.
56. P.Dong, X.Fu, X.Wang, W.M.Wang, W.M.Cao, W.Y.Zhang. Protective Effects of Sesaminol on BEAS-2B Cells Impaired by Cigarette Smoke Extract. Cell Biochem Biophys 2015; 71:1207–1213.
57. H.Yao, I.Rahman. Current concepts on oxidative/carbonyl stress, inflammation and epigenetics in pathogenesis of chronic obstructive pulmonary disease. Toxicol Appl Pharmacol 2011; 254:72–85.
58. M.A.Mansour, M.N.Nagi, A.S.El-Khatib, A.M.Al-Bekairi. Effects of thymoquinone on antioxidant enzyme activities, lipid peroxidation and DT-diaphorase in different tissues of mice:a possible mechanism of action. Cell Biochem Funct 2002; 20:143–151.
59. N.Noda, K.Matsumoto, S.Fukuyama, Y.Asai, H.Kitajima, N.Seki, et al. Cigarette smoke impairs phagocytosis of apoptotic neutrophils by alveolar macrophages via inhibition of the histone deacetylase/Rac/CD9 pathways. Int Immunol 2013; 25:643–650.
60. Q.Pang, X.Liu, K.Shi, X.Zeng, H.Bao. Effects of cigarette smoke on phagocytosed function of monocyte-derived macrophage in chronic obstructive pulmonary disease patients. Zhonghua Yi Xue Za Zhi 2014; 94:895–898.
61. B.H.Ali, G.Blunden. Pharmacological and toxicological properties of Nigella sativa. Phytother Res 2003; 17:299–305.
62. B.R.Acharya, A.Chatterjee, A.Ganguli, S.Bhattacharya, G.Chakrabarti. Thymoquinone inhibits microtubule polymerization by tubulin binding and causes mitotic arrest following apoptosis in A549 cells. Biochimie 2014; 97:78–91.
63. N.Ismail, M.Ismail, M.Mazlan, L.A.Latiff, M.U.Imam, S.Iqbal, et al. Thymoquinone prevents beta-amyloid neurotoxicity in primary cultured cerebellar granule neurons. Cell Mol Neurobiol 2013; 33:1159–1169.
64. R.Wilkins, M.Tucci, H.Benghuzzi. Evaluation of raw 264.7 macrophages treated with epigallocatechin-3-gallate and thymoquinone. Biomed Sci Instrum 2009; 45:346–351.
65. M.F.Zafeer, M.Waseem, S.Chaudhary, S.Parvez. Cadmium-induced hepatotoxicity and its abrogation by thymoquinone. J Biochem Mol Toxicol 2012; 26:199–205.
66. M.A.Mansour, O.T.Ginawi, T.El-Hadiyah, A.S.El-Khatib, O.A.Al-Shabanah, H.A.Al-Sawaf. Effects of volatile oil constituents of Nigella sativa on carbon tetrachloride-induced hepatotoxicity in mice:evidence for antioxidant effects of thymoquinone. Res Commun Mol Pathol Pharmacol 2001; 110:239–251.
67. O.A.Badary, M.N.Nagi, O.A.al-Shabanah, H.A.al-Sawaf, M.O.al-Sohaibani, A.M.al-Bekairi. Thymoquinone ameliorates the nephrotoxicity induced by cisplatin in rodents and potentiates its antitumor activity. Can J Physiol Pharmacol 1997; 75:1356–1361.
68. P.J.Houghton, R.Zarka, B.de las Heras, J.R.Hoult. Fixed oil of Nigella sativa and derived thymoquinone inhibit eicosanoid generation in leukocytes and membrane lipid peroxidation. Planta Med 1995; 61:33–36.
69. J.Akhondian, H.Kianifar, M.Raoofziaee, A.Moayedpour, M.B.Toosi, M.Khajedaluee. The effect of thymoquinone on intractable pediatric seizures [pilot study]. Epilepsy Res 2011; 93:39–43.
70. A.O.B.A.M.Al-Amri Phase I safety and clinical activity study of thymoquinone in patients with advanced refractory malignant disease. Shiraz E-Med 2009:107–111.
71. X.Feng, T.Deng, Y.Zhang, S.Su, C.Wei, D.Han. Lipopolysaccharide inhibits macrophage phagocytosis of apoptotic neutrophils by regulating the production of tumour necrosis factor alpha and growth arrest-specific gene 6. Immunology 2011; 132:287–295.
72. R.S.Wonderling, A.Ghaffar, E.P.Mayer. Lipopolysaccharide-induced suppression of phagocytosis:effects on the phagocytic machinery. Immunopharmacol Immunotoxicol 1996; 18:267–289.
73. A.L.Fuentes, L.Millis, J.Vapenik, L.Sigola. Lipopolysaccharide-mediated enhancement of zymosan phagocytosis by RAW 264.7 macrophages is independent of opsonins, laminarin, mannan, and complement receptor 3. J Surg Res 2014; 189:304–312.
74. S.N.Vogel, S.T.Marshall, D.L.Rosenstreich. Analysis of the effects of lipopolysaccharide on macrophages:differential phagocytic responses of C3H/HeN and C3H/HeJ macrophages in vitro. Infect Immun 1979; 25:328–336.
75. T.T.Wu, T.L.Chen, R.M.Chen. Lipopolysaccharide triggers macrophage activation of inflammatory cytokine expression, chemotaxis, phagocytosis, and oxidative ability via a toll-like receptor 4-dependent pathway:validated by RNA interference. Toxicol Lett 2009; 191:195–202.
76. M.A.Islam, M.U.Cinar, M.J.Uddin, E.Tholen, D.Tesfaye, C.Looft, et al. Expression of Toll-like receptors and downstream genes in lipopolysaccharide-induced porcine alveolar macrophages. Vet Immunol Immunopathol 2012; 146:62–73.
77. M.J.Uddin, P.K.Nuro-Gyina, M.A.Islam, D.Tesfaye, E.Tholen, C.Looft, et al. Expression dynamics of Toll-like receptors mRNA and cytokines in porcine peripheral blood mononuclear cells stimulated by bacterial lipopolysaccharide. Vet Immunol Immunopathol 2012; 147:211–222.
78. S.Michlewska, I.Dransfield, I.L.Megson, A.G.Rossi. Macrophage phagocytosis of apoptotic neutrophils is critically regulated by the opposing actions of pro-inflammatory and anti-inflammatory agents:key role for TNF-alpha. FASEB J 2009; 23:844–854.
79. Y.M.Janssen-Heininger, R.L.Persinger, S.H.Korn, C.Pantano, B.McElhinney, N.L.Reynaert, et al. Reactive nitrogen species and cell signaling:implications for death or survival of lung epithelium. Am J Respir Crit Care Med 2002; 166:S9–S16.
80. I.Rahman, J.Marwick, P.Kirkham. Redox modulation of chromatin remodeling:impact on histone acetylation and deacetylation, NF-kappaB and pro-inflammatory gene expression. Biochem Pharmacol 2004; 68:1255–1267.
81. J.Rivera, R.L.Proia, A.Olivera. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol 2008; 8:753–763.